Apigenin in cancer therapy: Prevention of genomic instability and anticancer mechanisms

Area of Science:

• Oncology
• Pharmacology
• Natural Products

Background:

• Global cancer incidence is rising, leading to concerns about long-term therapy side effects like secondary malignancies.
• Tumor resistance to anticancer agents is a significant challenge in cancer research.
• Low-toxicity adjuvants, such as herb-derived molecules, are being explored for chemoprevention and overcoming resistance.

Purpose of the Study:

• To review the multifaceted effects of apigenin on both normal tissues and malignancies.
• To elucidate apigenin's potential role in protecting normal cells from genotoxic damage caused by cancer therapies.
• To discuss the tumor-inhibitory properties of apigenin and its potential as an adjuvant therapy.

Main Methods:

• Literature review of preclinical and clinical studies on apigenin.
• Analysis of apigenin's molecular mechanisms in normal and cancerous cells.
• Evaluation of apigenin's efficacy in chemoprevention and as an adjunct to conventional cancer treatments.

Main Results:

• Apigenin exhibits promising anti-tumor effects and may reduce genomic instability.
• It demonstrates potential in protecting normal tissues from genotoxic damage induced by chemotherapy and radiotherapy.
• Apigenin may enhance the efficacy of existing anticancer modalities and help overcome tumor resistance.

Conclusions:

• Apigenin is a promising natural compound for cancer chemoprevention and as an adjuvant to cancer therapy.
• Its ability to protect normal cells and inhibit tumor growth warrants further investigation.
• Apigenin could play a role in reducing the long-term adverse effects of cancer treatment and improving patient outcomes.